Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2010-01-31
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of Walk Assist Device to Improve Community Ambulation
NCT01994395
Safety and Usability of the Honda Walking Assist Device (HWA) in the Home Environment
NCT04380363
Post Stroke Walking Kinematics Using the Honda Walking Assist Robotic Exoskeleton
NCT03828214
Development and Efficacy of a Novel, Cost-Effective Gait Training Device Utilized at Home for Stroke Survivors
NCT07250425
Walking Therapy In Hemiparetic Stroke Patients Using Robotic-Assisted Treadmill Training
NCT00075283
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The SMA assists walking by providing a flexion and extension torque assist at the hip joint. The subjects in this study are asked to perform two sets of experiments: one set with the device on and one set with the device turned off. The order in which the subjects performed these sets of experiments is selected randomly. Each set of experiments includes over-ground walking speed and endurance tests, a graded treadmill test with metabolic measures, motion capture and force treadmill analysis, and measures of corticospinal drive using transcranial magnetic stimulation (TMS). The primary outcome to be measured is change in self-selected walking speed with the device on, the secondary outcome measures include metabolic, corticospinal and biomechanical analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treadmill
Honda Stride Assist Device ON
Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
No Device Worn
Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
Overground Walking
Honda Stride Assist Device ON
Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
No Device Worn
Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Honda Stride Assist Device ON
Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
No Device Worn
Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. All subjects who score \> 10 on the Lower Extremity Motor Score (LEMS) developed previously to measure strength in Spinal Cord Injury (SCI). For the LEMS criteria, preliminary data indicate that subjects with LEMS \< 10 in the chronic stages do not recover walking.
3. All subjects will be required to walk \> 10 m over ground without physical assistance at self-selected walking speeds ≤ 0.8 m/s using assistive devices and bracing below the knee as needed. A criterion of 0.8 m/s is utilized to target participants with limited or minimal ambulation in the community. Subjects will be further stratified into those who walk \< 0.4 m/s and \> 0.4 m/s, identified as household vs. limited community ambulators, respectively.
4. Range of motion (ankle: -10 to 30 deg, knee: 0 to 90 deg, hip: -10 to 40 deg) consistent with gait;
5. Medically stable with medical clearance to participate (absence of concurrent illness, including unhealed decubiti, infection, cardiopulmonary disease, osteoporosis, active heterotrophic ossification or peripheral nerve damage in the lower limbs, history of traumatic head injury);
6. Able to tolerate 30 minutes of upright (standing) position without orthostasis (decrease in blood pressure by 20 mmHg systolic and 10 mmHg diastolic; minimized with ambulatory population);
7. Must not be undergoing concurrent physical therapy to eliminate effects of additional interventions;
8. Patients prescribed medications for spasticity will not be excluded from participation but will be asked to maintain current levels of medication or inform the researcher if changes are necessary.
\-
Exclusion Criteria
2. Significant cardiorespiratory or metabolic disease that may limit exercise participation.
3. Weights limit \> 250 lbs (limit of most counter-weight safety systems).
4. History of previous orthopedic or neurological conditions which may impair walking.
5. Exclusion for TMS: pacemaker, metal implants in the head region, history of epilepsy or seizures, skull fractures or skull deficits, concussion within the last 6 months, unexplained recurring headaches, medications that lower seizure threshold, and pregnancy.
6. Subjects with scores \< 23 on the Mini Mental Status Exam will be excluded.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shirley Ryan AbilityLab
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arun Jayaraman, PT, PhD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arun Jayaraman, PT, PhD
Role: PRINCIPAL_INVESTIGATOR
Shirley Ryan AbilityLab
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rehabilitation Institute of Chicago
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NUSTU00022438
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.